Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evernic acid is a natural depside and secondary metabolite primarily isolated from lichen species such as *Evernia prunastri* (oakmoss). It is being extensively researched for its potential as an adjuvant in oncology, where it has demonstrated the ability to enhance the sensitivity of cancer cells to traditional chemotherapeutic agents like temozolomide and paclitaxel. Its mechanism of action involves the modulation of the Wnt signaling pathway and the exertion of immunomodulatory effects, which help overcome drug resistance in glioblastoma and breast cancer models. Additionally, evernic acid exhibits significant anti-inflammatory and antioxidant properties, leading to investigations into its neuroprotective potential, particularly in mitigating neuroinflammation and dopaminergic neuronal loss in models of Parkinson's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on evernic acid.